Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

October 2016

P&T Committee Updates


At the September 12, 2016 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed 3 medications and decided the following:

P&T Committee Review and Decisions

Name

Description and Indication

Decision

Incruse Ellipta (umeclidinium)  

Incruse Ellipta is an anticholinergic indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

  • Premium formulary: Added to preferred brand tier
  • Value formulary: Added to preferred brand tier
  • Medicare Advantage Formulary: Added to preferred brand tier

Stiolto Respimat (tiotropium bromide/olodaterol) 

Stiolto Respimat — a combination of tiotropium, an anticholinergic, and olodaterol, a long-acting beta2-adrenergic agonist (LABA) — is indicated for the long-term, once-daily maintenance treatment of airflow obstruction inpatients with chronic obstructive pulmonary disease (COPD).

  • Premium formulary: Continued coverage at non-preferred brand tier
  • Value formulary: Remains non-covered
  • Medicare Advantage formulary: Added to preferred brand tier

Anoro Ellipta (umeclidinium/vilanterol) 

Anoro Ellipta — a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) — is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

  • Premium formulary: Added to preferred brand tier
  • Value formulary: Added to preferred brand tier
  • Medicare Advantage formulary: Continued coverage at preferred brand tier

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Harvard Pilgrim Among NCQA’s Highest-Rated Private Health Plans in the U.S.

Medicare Advantage Updates: Expansion and Prior Authorization Policies

Harvard Pilgrim Introduces ElevateHealth Options in New Hampshire

Habilitative Benefit Requirement and Rehabilitative Benefit Changes

CLINICIAN CORNER

Medicare Prescriber Enrollment Deadline Updated

Reminder: Billing for Additional Antepartum E&M Visits

2017 CPT and HCPCS codes

Update to Formulas and Enteral Nutrition Prior Authorization Policy

Updates to Cardiovascular Disease Risk Tests Policy

Medicare Advantage Blood Glucose Monitoring Supplies

P&T Committee Updates

Specialty Pharmacy Program Updates

Updates to Clinical Medical Policies

ADHD Diagnosis and Follow-up Care

OFFICE ASSISTANT

Outpatient Fee Schedule Updates

Assisting our Nurse Case Managers with Requests for Information

Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator